Answers are grounded in this paper and cite their sources.
Subsequent malignant neoplasms (SMNs) developing after hematopoietic cell transplantation (HCT) are a well-described complication [1-6]. The magnitude of risk of SMNs after HCT ranges from four-fold to 11-fold that of the general population. The estimated actuarial incidence is reported to be 3.5% at 10 years, increasing to 12.8% at 15 years among recipients of allogeneic HCT. The differing clinicopathologic characteristics of SMNs preclude assessment of risk factors in aggregate. It has become conventional practice to classify SMNs into three distinct groups [7]: (1) myelodysplasia (t-MDS)/acute myeloid leukemia (t-AML); (2) lymphoma, including lymphoproliferative disorders; and (3) solid tumors.
No takes yet. Share an insight, caveat, or question.
Socié et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: